Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium/formoterol versus salmeterol/fluticasone in symptomatic COPD
NL-OMON40490Phase 3Active, not recruiting
- Sponsor
- Almirall
- Start
- Nov 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Aclidinium bromide + formoterol fumarate with Salmeterol + fluticasone propionate (2 arms). Primary endpoint: Peak FEV1 at week 24. Started Nov 2013; status: active, not recruiting.
02
Drugs
aclidiniumformoterolsalmeterolfluticasone propionate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON40490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40490.